05686072 is referenced by 133 patents and cites 5 patents.

The anti-tumor activity of a mixture of anti-CD22 and anti-CD19 immunotoxins is shown to be significantly enhanced in SCID/Daudi mice with disseminated human Daudi lymphoma. Unexpectedly identical enhancement was observed employing a combination of the anti-CD22 immunotoxin with unconjugated anti-CD19 antibodies. Thus combinations of an anti-CD22 immunotoxin and an anti-CD19 immunotoxin or antibody act synergistically and provide advantageous compositions and methods for immunotherapeutic treatment of various diseases including cancer and autoimmune disorders. Also disclosed is data indicating that certain anti-CD19 antibodies alone inhibit proliferation of CD19-positive cells by inducing cell cycle arrest.

Title
Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
Application Number
899781
Publication Number
5686072
Application Date
February 22, 1994
Publication Date
November 11, 1997
Inventor
Richard H Scheuermann
Carrollton
TX, US
Ellen S Vitetta
Dallas
TX, US
Jonathan W Uhr
Dallas
TX, US
Agent
Arnold White & Durkee
Assignee
Board of Regents The University of Texas
TX, US
IPC
A61K 39/395
View Original Source